Why Epizyme Inc. Shares Rocketed Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Epizyme (NASDAQ: EPZM  ) , a clinical-stage biopharmaceutical company with a therapeutic focus on treating cancer, soared as much as 18% after the company announced that it received a milestone and licensing payment for reaching a third target in an ongoing collaboration with GlaxoSmithKline  (NYSE: GSK  ) .

So what: According to the press release, Epizyme received $4 million for discovering the third of three histone methyltransferase, or HMT, targets in collaboration with GlaxoSmithKline using its proprietary discovery platform. This marks the third such instance since January in which GlaxoSmithKline has given Epizyme a milestone and licensing payment (the other two totaled $2 million and $4 million).

Now what: Epizyme isn't exactly hurting for cash, holding $123.6 million in the bank as of the latest quarter. However, given that the company is burning through through $50 million annually with ongoing trials and research, even a $4 million payment can be seen in positive light. The real excitement revolves around how seemingly quickly Epizyme was able to discover three HMT compounds, which lends a lot of hope that Epizyme could make many additional discoveries along this pathway in a short amount of time. Of course, we're also talking about very, very early stage ideas here, so it'd be wise for shareholders not to get too caught up in that noise until we have some clinically concrete data.

Epizyme shares may be soaring today, but they'll likely struggle to keep pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 03, 2014, at 1:47 PM, SonicFoolAz wrote:

    While this looks to be a promising company current values and potentials which are 10+ years out don't come anywhere near close enough to justify the current market price.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2924152, ~/Articles/ArticleHandler.aspx, 8/29/2015 12:59:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 15 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 3:59 PM
EPZM $20.10 Up +2.60 +14.86%
Epizyme CAPS Rating: ****
GSK $41.25 Up +0.04 +0.10%
GlaxoSmithKline CAPS Rating: ****